Company intelligence / Profile preview
Circle33
Lexington, Massachusetts, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
AVX-470 successfully completed Phase 1b clinical trial in adults with active ulcerative colitis, demonstrating anti-TNF biological activity and proof of mechanism in IBD patients with minimal systemic exposure and low immunogenicity[1][4]. The company received orphan drug status from the FDA for pediatric IBD[1].
- Therapeutic areas
- Gastroenterology
- Modalities
- Monoclonal antibodyRecombinant protein
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Investment from online lender LendUp (approximately $30M in R&D and clinical trials)[1]
Beyond the preview
Go deeper on Circle33.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Circle33.